Oral ingestion of<i>Streptococcus thermophilus</i>does not affect mucositis severity or tumor progression in the tumor-bearing rat

Tooley, Katie L.; Howarth, Gordon S.; Lymn, Kerry A.; Lawrence, Andrew J; Butler, Ross N.

doi:10.4161/cbt.12.2.15720

Cited by 21 publications

(16 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pretreatment with probiotic had no influence on the food intake and weight loss. Tooley et al [24] found similar results using Streptococcus thermophilus as probiotic. In their work, animals that received probiotic treatment and were subjected to mucositis induction showed weight losses similar to those of animals that did not receive the probiotic treatment.…”

Section: Discussionmentioning

confidence: 70%

Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice

Maioli

Silva

Dias

et al. 2014

J Negat Results BioMed

View full text Add to dashboard Cite

BackgroundThe antimetabolite chemotherapy 5-Fluorouracil is one of the most commonly prescribed drugs in clinical cancer treatment. Although this drug is not specific for cancer cells and also acts on healthy cells, it can cause mucositis, a common collateral effect. Dysbiosis has also been described in 5-fluorouracil-induced mucositis and is likely to contribute to the overall development of mucositis. In light of this theory, the use of probiotics could be a helpful strategy to alleviate mucositis. So the aim of this study was evaluate the impact of the probiotic Saccharomyces boulardii in a model of mucositis.ResultsAfter induced of mucositis, mice from the Mucositis groups showed a decrease in food consumption (p < 0.05) and therefore had a greater weight loss (p < 0.05). The treatment with Saccharomyces boulardii did not reverse this effect (p > 0.05). Mucositis induced an increase in intestinal permeability and intestinal inflammation (p < 0.05). There were no differences in mucosal lesions, intestinal permeability and sIgA secretion (p > 0.05) in mice pretreated with S. boulardii.ConclusionsS. boulardii was not able to prevent the effects of experimental mucositis induced by 5- Fluorouracil.

show abstract

Section: Discussionmentioning

confidence: 70%

Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice

Maioli

Silva

Dias

et al. 2014

J Negat Results BioMed

View full text Add to dashboard Cite

show abstract

“…As an example to illustrate these difficulties, oral ingestions of Streptococcus thermophilus led to the attenuation of intestinal damage in nontumour‐bearing rats treated with methotrexate . However, a subsequent study investigating the effects of S. thermophilus in tumour‐bearing rats treated with methotrexate did not demonstrate any beneficial effect . There is no evidence of the benefits of prebiotics or synbiotics in this setting.…”

Section: Methodsmentioning

confidence: 99%

Systematic review: the role of the gut microbiota in chemotherapy‐ or radiation‐induced gastrointestinal mucositis – current evidence and potential clinical applications

Touchefeu

Montassier

Nieman³

et al. 2014

Aliment Pharmacol Ther

362

281

View full text Add to dashboard Cite

show abstract

“…Lactic acid bacteria have also been studied and has generated promising results, both in vitro and in vivo , in other models of intestinal inflammation, such as preclinical mucositis models (Tooley et al, 2006; Bowen et al, 2007; Smith et al, 2008; Southcott et al, 2008; Whitford et al, 2009; Tooley et al, 2011; Prisciandaro et al, 2012). In vitro , it was observed that IECs previously treated with 5-FU presented reduced levels of cytotoxicity and apoptosis through the inhibition of caspase-3 and caspase-7 when co-cultured with L. rhamnosus (Prisciandaro et al, 2012).…”

Section: Use Of Probiotic Lactic Acid Bacteria In the Treatment Of Gamentioning

confidence: 99%

“…They showed that live TH-4 significantly reduced disease severity scores as well as crypt fission indices, which is an indicator of longitudinal intestinal growth and stem cell proliferation, suggesting that this strain may be useful for treating diseases characterized by increased crypt fission, such as colorectal carcinoma. However, Tooley et al (2011) ascertained the effects of live TH-4 on small intestinal damage generated by the injection of methotrexate (MTX), a chemotherapy drug that induces mucositis and tumor progression in tumor-bearing rats. This study verified that although TH-4 did not protect animals from chemotherapy-induced mucositis, the progression of mammary adenocarcinoma was unaffected (Tooley et al, 2011).…”

Section: Use Of Probiotic Lactic Acid Bacteria In the Treatment Of Gamentioning

confidence: 99%

“…However, Tooley et al (2011) ascertained the effects of live TH-4 on small intestinal damage generated by the injection of methotrexate (MTX), a chemotherapy drug that induces mucositis and tumor progression in tumor-bearing rats. This study verified that although TH-4 did not protect animals from chemotherapy-induced mucositis, the progression of mammary adenocarcinoma was unaffected (Tooley et al, 2011). …”

Section: Use Of Probiotic Lactic Acid Bacteria In the Treatment Of Gamentioning

confidence: 99%

See 1 more Smart Citation

Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis

et al. 2017

View full text Add to dashboard Cite

The human gastrointestinal tract (GIT) is highly colonized by bacterial communities, which live in a symbiotic relationship with the host in normal conditions. It has been shown that a dysfunctional interaction between the intestinal microbiota and the host immune system, known as dysbiosis, is a very important factor responsible for the development of different inflammatory conditions of the GIT, such as the idiopathic inflammatory bowel diseases (IBD), a complex and multifactorial disorder of the GIT. Dysbiosis has also been implicated in the pathogenesis of other GIT inflammatory diseases such as mucositis usually caused as an adverse effect of chemotherapy. As both diseases have become a great clinical problem, many research groups have been focusing on developing new strategies for the treatment of IBD and mucositis. In this review, we show that lactic acid bacteria (LAB) have been capable in preventing and treating both disorders in animal models, suggesting they may be ready for clinical trials. In addition, we present the most current studies on the use of wild type or genetically engineered LAB strains designed to express anti-inflammatory proteins as a promising strategy in the treatment of IBD and mucositis.

show abstract

Oral ingestion ofStreptococcus thermophilusdoes not affect mucositis severity or tumor progression in the tumor-bearing rat

Cited by 21 publications

References 42 publications

Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice

Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice

Systematic review: the role of the gut microbiota in chemotherapy‐ or radiation‐induced gastrointestinal mucositis – current evidence and potential clinical applications

Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis

Contact Info

Product

Resources

About